शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEBDH Industries Ltd· Pharmaceuticals & BiotechnologyHighPositive
Announced Fri, 23 May, 2025 · 19:13 IST

The Board of Directors of the Company at their meeting held today have recommended a dividend of Rs. 4.50/- per equity share of the face value of Rs. 10/- each subject to approval of the ....

Revenue DeclineEbitda Margin ExpansionResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-8.2%Reaction day
₹266.90
prior close
₹262.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-8.8% vs market
Pharmaceuticals peers, median of 148sector+0.4%-8.6% vs sector

On the reaction day the stock moved 8.8 pts less than Nifty Microcap 250 and 8.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-8.0
10m
-6.1
15m
-5.7
30m
-6.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-8.2+0.6-8.8+0.4-8.6
Next day
-6.3+0.5-6.8+0.4-6.7
2d
-6.3+0.8-7.1+0.5-6.8
3d
-5.7+1.2-6.9+1.1-6.8
4d
-6.4+1.5-7.8+0.6-7.0
5d
-5.6+1.6-7.1-0.0-5.6
1w
-7.1+1.8-8.9+0.3-7.4
15d
+0.1+3.3-3.2+1.8-1.6
1m
+1.5+3.1-1.6-1.2+2.7
2m
+21.0+2.3+18.8+0.6+20.5
3m
+15.6+0.2+15.4-1.8+17.3
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

BDH Industries' board met on 23 May 2025 and approved audited FY25 standalone results along with a recommended dividend of Rs. 4.50 per share (45% on face value of Rs. 10), subject to shareholder approval at the 35th AGM on 8 August 2025. Revenue from operations declined to Rs. 6,650.83 lakhs from Rs. 8,583.10 lakhs in FY24, a drop of about 22.5%, while profit after tax fell to Rs. 927.33 lakhs from Rs. 986.78 lakhs (about 6% lower). Despite the topline decline, operating profit margins improved meaningfully, and operating cash flow swung sharply positive to Rs. 1,477 lakhs from a negative Rs. 187 lakhs last year, driven by better receivables collection and lower borrowings (down to Rs. 97.97 lakhs from Rs. 869.07 lakhs). The statutory auditor (CLB & Associates) issued an unmodified (clean) opinion. The board also recommended reappointment of Ms. Jayashree Nair as Managing Director for three years from 1 April 2026 and re-designation/reappointment of Mr. S.C. Kachhara as Managing Director, along with appointment of internal, cost, and secretarial auditors for FY26.

Likely market impact

Shareholders get a healthy 45% dividend, but the sharp revenue decline in FY25 may weigh on sentiment even though margins and cash flows strengthened. The clean audit opinion, debt reduction, and strong operating cash flow are positives for stability, while continuity of the promoter-led leadership provides management consistency.